Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsBiotechnology Equipment

PUBLISHER: Roots Analysis | PRODUCT CODE: 1549403

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1549403

Molecular Diagnostics Market Distribution by Product, by Technology, by Application, by Sample Type, by End Users and Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035

PUBLISHED:
PAGES: 224 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

The Molecular Diagnostics Market is valued at USD 15.9 billion in 2024 growing at a CAGR of 6.2% during the forecast period 2024-2035.

Molecular diagnostic tests are designed to detect specific sequences in human genomic samples, such as DNA or RNA, to diagnose specific diseases. These tests also aim to identify single nucleotide polymorphisms, deletions, rearrangements, and insertions in genetic sequences. It is worth noting that molecular diagnostics is a subset of the in vitro diagnostics market, which, according to the World Health Organization, consists of over 40,000 available products. This vast array of products highlights the critical role of diagnostics in healthcare, with over 70% of healthcare decisions being made based on laboratory test results, showcasing the importance of such diagnostic tools in patient care.

Molecular diagnostic tests play a pivotal role in diagnosing various diseases, monitoring healthcare responses, and predicting healthcare outcomes. Given the benefits offered by such diagnostic solutions in providing rapid results and improving patient outcomes, the global molecular diagnostics market is expected to experience substantial growth at a healthy CAGR during the forecast period. This market growth can be attributed to several factors, including the increasing demand for point-of-care diagnostics devices, rapid diagnostic testing, and the rising prevalence of infectious diseases.

Key Market Segments

Test Type

  • Laboratory Testing
  • Point-of-Care Testing

Type of Offering / Product Type

  • Reagents
  • Instruments
  • Services

Type of Sample

  • Blood, Serum and Plasma
  • Urine
  • Others

Type of Technology

  • Polymerase Chain Reaction (PCR)
  • In situ Hybridization
  • Isothermal Nucleic Acid Amplification Technology
  • Next Generation Sequencing
  • Microarrays
  • Mass Spectrometry
  • Others

Therapeutic Area

  • Cardiovascular Diseases
  • Genetic Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Oncological Disorders
  • Others

End Users

  • Hospitals
  • Laboratories
  • Others

Geographical Regions

  • North America (US, Canada)
  • Europe (Austria, Belgium, France, Germany, Italy, Netherlands,

Poland, Spain, Switzerland, UK, Rest of the Europe)

  • Asia (China, India, Indonesia, Japan, Singapore,

South Korea, Thailand, Rest of Asia)

  • Latin America (Argentina, Brazil, Mexico,

Rest of Latin America)

  • Middle East and North Africa (Egypt, Israel, Saudi Arabia,

Rest of Middle East and North Africa)

  • Rest of the World (Australia and New Zealand)

Research Coverage:

  • A brief overview of molecular diagnostics, featuring information on key technologies employed in molecular diagnostic solutions and challenges associated with molecular diagnostics domain. Further, this chapter features recent advancements and future perspectives of this market space.
  • An in-depth analysis of the factors that can impact the growth of the market. It also features identification and market analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed estimate of the current molecular diagnostics market size, opportunity and the future growth potential, over the next decade. Based on multiple parameters, likely adoption trends and through validations from credible sources, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also features likely distribution of the current and forecasted opportunity. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
  • A detailed projection of current market size and future opportunity in the molecular diagnostics market across different test types, such as laboratory testing and point-of-care testing.
  • A detailed projection of the current and future molecular diagnostics industry across different types of offerings, such as instruments, reagents and services.
  • A detailed projection of the current and future market for molecular diagnostics across different types of samples, such as blood, serum and plasma, urine and others.
  • A detailed projection of the current and future molecular diagnostics market across different types of technologies, such as PCR, in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, microarrays, mass spectrometry and others.
  • A detailed projection of the current and future molecular diagnostic industry across different therapeutic areas, such as cardiovascular diseases, genetic diseases, infectious diseases, neurological diseases, oncological disorders and others.
  • A detailed projection of the current and future molecular diagnostics market across different end users, such as hospitals, laboratories and others.
  • A detailed projection of the current and future molecular diagnostic industry across Geographical Regions, such as North America (US, Canada), Europe (Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, UK, Rest of the Europe), Asia (China, India, Indonesia, Japan, Singapore, South Korea, Thailand, Rest of Asia), Latin America (Argentina, Brazil, Mexico, Rest of Latin America), Middle East and North Africa (Egypt, Israel, Saudi Arabia, Rest of Middle East and North Africa) and Rest of the World (Australia and New Zealand).
  • A detailed analysis showcasing the segmentation of the molecular diagnostics industry among the leading players engaged in this domain.
  • An overview of the current market landscape of leading molecular diagnostics companies, along with company overview (information on their year of establishment, company size, company ownership and location of headquarters). Further, it highlights a detailed assessment of the molecular diagnostic solutions based on several relevant parameters, such as type of technology used (PCR, next generation sequencing, microarrays, mass spectrometry, isothermal nucleic acid amplification technology, and in situ hybridization), diagnostic applications (infectious, genetic, gynecological, oncological, sexually transmitted infections / diseases, and neurological).
  • An insightful competitiveness analysis of the leading molecular diagnostics companies, based on several relevant parameters, such as years of experience and company competitiveness (based on annual revenue, type of technology and diagnostic applications).
  • Elaborate profiles of various prominent players segregated based on various geographical regions, that are currently involved in the molecular diagnostics market. Each company profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and key members of the executive team), financial information, molecular diagnostic offerings and details related to its recent developments and an informed future outlook.
  • A qualitative porter's five forces analysis, highlighting the five competitive forces prevalent in the market, including threats for new entrants, bargaining power of buyers, bargaining power of suppliers, threats of substitute products and rivalry among existing competitors.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the Molecular Diagnostics Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Abbott Laboratories
  • Agilent Technologies
  • Becton Dickinson
  • BGI Genomics
  • bioMerieux
  • Bio-Rad
  • Danaher
  • DiaSorin
  • Grifols
  • Hologic
  • Illumina
  • Qiagen
  • QuidelOrtho
  • Revvity
  • Roche
  • Sansure
  • Seegene
  • Siemens Healthineers
  • Sysmex
  • Thermo Fisher Scientific
Show more
Product Code: RA100507

TABLE OF CONTENTS

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Factors
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future
    • 3.2.2. Currency Coverage and Foreign Exchange Rate
      • 3.2.2.1. Major Currencies Affecting the Market
      • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
      • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
      • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.3. Trade Policies
      • 3.2.3.1. Impact of Trade Barriers on the Market
      • 3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Overview of Molecular Diagnostics
  • 5.2. Key Technologies Employed in Molecular Diagnostic Solution
  • 5.3. Challenges in the Molecular Diagnostics Domain
  • 5.4. Recent Developments in the Molecular Diagnostics Domain
  • 5.5. Future Perspective in the Molecular Diagnostics Domain

6. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 6.1. Market Drivers
  • 6.2. Market Restraints
  • 6.3. Market Opportunities
  • 6.4. Market Challenges

7. GLOBAL MOLECULAR DIAGNOSTICS MARKET

  • 7.1. Key Assumptions and Methodology
  • 7.2. Global Molecular Diagnostics Market, Till 2035
    • 7.2.1. Scenario Analysis
      • 7.2.1.1. Conservative Scenario
      • 7.2.1.2. Optimistic Scenario

8. MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE

  • 8.1. Market Movement Analysis
  • 8.2. Molecular Diagnostics Market: Distribution by Test Type (Current Year and 2035)
    • 8.2.1. Molecular Diagnostics Market for Laboratory Testing, Till 2035
    • 8.2.2. Molecular Diagnostics Market for Point-of-Care Testing, Till 2035

9. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF OFFERING

  • 9.1. Market Movement Analysis
  • 9.2. Molecular Diagnostics Market: Distribution by Type of Offering (Current Year and 2035)
    • 9.2.1. Molecular Diagnostics Market for Instruments, Till 2035
      • 9.2.1.1. Molecular Diagnostics Market for In-house Instruments, Till 2035
      • 9.2.1.2. Molecular Diagnostics Market for Outsourced Instruments, Till 2035
    • 9.2.2. Molecular Diagnostics Marlet for Reagents, till 2035
    • 9.2.3. Molecular Diagnostics Market for Services, till 2035

10. MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

  • 10.1. Market Movement Analysis
  • 10.2. Molecular Diagnostics Market: Distribution by Sample Type (Current Year and 2035)
    • 10.2.1. Molecular Diagnostics Market for Blood, Serum and Plasma, till 2035
    • 10.2.2. Molecular Diagnostics Market for Urine, till 2035
    • 10.2.3. Molecular Diagnostics Market for Other Samples, till 2035

11. MOLECULAR DIAGNOSTICS MARKET, BY TYPE OF TECHNOLOGY

  • 11.1. Market Movement Analysis
  • 11.2. Molecular Diagnostics Market: Distribution by Type of Technology (Current Year and 2035)
    • 11.2.1. Molecular Diagnostics Market for PCR, till 2035
    • 11.2.2. Molecular Diagnostics Market for In situ Hybridization, till 2035
    • 11.2.3. Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, till 2035
    • 11.2.4. Molecular Diagnostics Market for Next Generation Sequencing, till 2035
    • 11.2.5. Molecular Diagnostics Market for Microarrays, till 2035
    • 11.2.6. Molecular Diagnostics Market for Mass Spectrometry, till 2035
    • 11.2.7. Molecular Diagnostics Market for Other Technologies, till 2035

12. MOLECULAR DIAGNOSTICS MARKET, BY THERAPEUTIC AREA

  • 12.1. Market Movement Analysis
  • 12.2. Molecular Diagnostics Market: Distribution by Therapeutic Area (Current Year and 2035)
    • 12.2.1. Molecular Diagnostics Market for Infectious Diseases, till 2035
      • 12.2.1.1. Molecular Diagnostics Market for COVID-19, till 2035
      • 12.2.1.2. Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), till 2035
      • 12.2.1.3. Molecular Diagnostics Market for Healthcare-associated Infections, till 2035
      • 12.2.1.4. Molecular Diagnostics Market for Hepatitis, till 2035
      • 12.2.1.5. Molecular Diagnostics Market for HIV, till 2035
      • 12.2.1.6. Molecular Diagnostics Market for Sexually Transmitted Diseases, till 2035
      • 12.2.1.7. Molecular Diagnostics Market for Other Infectious Diseases, till 2035
    • 12.2.2. Molecular Diagnostics Market for Oncological Disorders, till 2035
      • 12.2.2.1. Molecular Diagnostics Market for Lung Cancer, till 2035
      • 12.2.2.2. Molecular Diagnostics Market for Breast Cancer, till 2035
      • 12.2.2.3. Molecular Diagnostics Market for Colorectal Cancer, till 2035
      • 12.2.2.4. Molecular Diagnostics Market for Prostate Cancer, till 2035
      • 12.2.2.5. Molecular Diagnostics Market for Gastric Cancer, till 2035
      • 12.2.2.6. Molecular Diagnostics Market for Other Oncological Disorders, till 2035
    • 12.2.3. Molecular Diagnostics Market for Cardiovascular Diseases, till 2035
    • 12.2.4. Molecular Diagnostics Market for Neurological Diseases, till 2035
    • 12.2.5. Molecular Diagnostics Market for Genetic Diseases, till 2035
    • 12.2.6. Molecular Diagnostics Market for Other Therapeutic Areas, till 2035

13. MOLECULAR DIAGNOSTICS MARKET, BY END USERS

  • 13.1. Market Movement Analysis
  • 13.2. Molecular Diagnostics Market: Distribution by End Users (Current Year and 2035)
    • 13.2.1. Molecular Diagnostics Market for Laboratories, till 2035
      • 13.2.1.1. Molecular Diagnostics Market for Large Laboratories, till 2035
      • 13.2.1.2. Molecular Diagnostics Market for Small and Medium-sized Laboratories, till 2035
    • 13.2.2. Molecular Diagnostics Market for Hospitals, till 2035
    • 13.2.3. Molecular Diagnostics Market for Other End Users, till 2035

14. MOLECULAR DIAGNOSTICS MARKET, BY GEOGRAPHICAL REGIONS

  • 14.1. Market Movement Analysis
  • 14.2. Molecular Diagnostics Market: Distribution by Geographical Regions (Current Year and 2035)
    • 14.2.1. Molecular Diagnostics Market in North America, till 2035
      • 14.2.1.1. Molecular Diagnostics Market in the US, till 2035
      • 14.2.1.2. Molecular Diagnostics Market in Canada, till 2035
    • 14.2.2. Molecular Diagnostics Market in Europe, till 2035
      • 14.2.2.1. Molecular Diagnostics Market in Austria, till 2035
      • 14.2.2.2. Molecular Diagnostics Market in Belgium, till 2035
      • 14.2.2.3. Molecular Diagnostics Market in France, till 2035
      • 14.2.2.4. Molecular Diagnostics Market in Germany, till 2035
      • 14.2.2.5. Molecular Diagnostics Market in Italy, till 2035
      • 14.2.2.6. Molecular Diagnostics Market in the Netherlands, till 2035
      • 14.2.2.7. Molecular Diagnostics Market in Poland, till 2035
      • 14.2.2.8. Molecular Diagnostics Market in Spain, till 2035
      • 14.2.2.9. Molecular Diagnostics Market in Switzerland, till 2035
      • 14.2.2.10. Molecular Diagnostics Market in the UK, till 2035
      • 14.2.2.11. Molecular Diagnostics Market in Rest of the Europe, till 2035
    • 14.2.3. Molecular Diagnostics Market in Asia, till 2035
      • 14.2.3.1. Molecular Diagnostics Market in China, till 2035
      • 14.2.3.2. Molecular Diagnostics Market in India, till 2035
      • 14.2.3.3. Molecular Diagnostics Market in Indonesia, till 2035
      • 14.2.3.4. Molecular Diagnostics Market in Japan, till 2035
      • 14.2.3.5. Molecular Diagnostics Market in Singapore, till 2035
      • 14.2.3.6. Molecular Diagnostics Market in South Korea, till 2035
      • 14.2.3.7. Molecular Diagnostics Market in Thailand, till 2035
      • 14.2.3.8. Molecular Diagnostics Market in Rest of Asia, till 2035
    • 14.2.4. Molecular Diagnostics Market in Latin America, till 2035
      • 14.2.4.1. Molecular Diagnostics Market in Brazil, till 2035
      • 14.2.4.2. Molecular Diagnostics Market in Argentina, till 2035
      • 14.2.4.3. Molecular Diagnostics Market in Mexico, till 2035
      • 14.2.4.4. Molecular Diagnostics Market in Rest of Latin America, till 2035
    • 14.2.5. Molecular Diagnostics Market in Middle East and North Africa, till 2035
      • 14.2.5.1. Molecular Diagnostics Market in Egypt, till 2035
      • 14.2.5.2. Molecular Diagnostics Market in Israel, till 2035
      • 14.2.5.3. Molecular Diagnostics Market in Saudi Arabia, till 2035
      • 14.2.5.4. Molecular Diagnostics Market in Rest of Middle East and North Africa, till 2035
    • 14.2.6. Molecular Diagnostics Market in Rest of the World, till 2035
      • 14.2.6.1. Molecular Diagnostics Market in Australia, till 2035
      • 14.2.6.2. Molecular Diagnostics Market in New Zealand, till 2035

15. MOLECULAR DIAGNOSTICS MARKET, BY LEADING PLAYERS

  • 15.1. Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues

16. MARKET OVERVIEW: LEADING MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

  • 16.1. Molecular Diagnostic Solution: Overall Market Landscape
    • 16.1.1. Analysis by Type of Technology
    • 16.1.2. Analysis by Diagnostic Applications
    • 16.1.3. Analysis by Type of Technology and Diagnostic Applications
  • 16.2. Molecular Diagnostics: Solution Providers Landscape
    • 16.2.1. Analysis by Year of Establishment
    • 16.2.2. Analysis by Company Size
    • 16.2.3. Analysis by Location of Headquarters
    • 16.2.4. Analysis by Company Ownership

17. COMPANY COMPETITIVENESS ANALYSIS: MOLECULAR DIAGNOSTIC SOLUTION PROVIDERS

  • 17.1. Methodology and Key Parameters Assessed
  • 17.2. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players
  • 17.3. Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players
  • 17.4. Benchmarking Analysis: Leading Molecular Diagnostics Solution Providers
    • 17.4.1. Benchmarking of Companies
      • 17.4.1.1. Roche: Benchmarking Analysis
      • 17.4.1.2. Abbott: Benchmarking Analysis
      • 17.4.1.3. Thermo Fisher Scientific: Benchmarking Analysis
      • 17.4.1.4. Qiagen: Benchmarking Analysis
      • 17.4.1.5. bioMerieux: Benchmarking Analysis
      • 17.4.1.6. DiaSorin: Benchmarking Analysis
      • 17.4.1.7. Illumina: Benchmarking Analysis
      • 17.4.1.8. Sysmex: Benchmarking Analysis
      • 17.4.1.9. Perkin Elmer: Benchmarking Analysis
      • 17.4.1.10. Bio-Rad: Benchmarking Analysis
    • 17.4.2. Benchmarking of Parameters
      • 17.4.2.1. Leading Molecular Diagnostics Solution Providers: Benchmarking by Competitiveness
      • 17.4.2.2. Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score
      • 17.4.2.3. Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score

18. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN NORTH AMERICA

  • 18.1. Detailed Company Profiles
    • 18.1.1. Abbott
      • 18.1.1.1. Company Overview
      • 18.1.1.2. Product Portfolio
      • 18.1.1.3. Financial Information
      • 18.1.1.4. Recent Developments and Future Outlook
    • 18.1.2. Agilent Technologies
    • 18.1.3. BD
    • 18.1.4. Danaher
    • 18.1.5. Thermo Fisher Scientific
  • 18.2. Short Company Profiles
    • 18.2.1. Bio-Rad
      • 18.2.1.1. Company Overview
      • 18.2.1.2. Product Portfolio
    • 18.2.2. Illumina
    • 18.2.3. Hologic
    • 18.2.4. PerkinElmer
    • 18.2.5. QuidelOrtho

19. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN EUROPE

  • 19.1. Detailed Company Profiles
    • 19.1.1. bioMerieux
      • 19.1.1.1. Company Overview
      • 19.1.1.2. Product Portfolio
      • 19.1.1.3. Financial Information
      • 19.1.1.4. Recent Developments and Future Outlook
    • 19.1.2. Grifols
    • 19.1.3. Roche
    • 19.1.4. Siemens Healthineers
  • 19.2. Brief Company Profiles
    • 19.2.1. DiaSorin
      • 19.2.1.1. Company Overview
      • 19.2.1.2. Product Portfolio
    • 19.2.2. Qiagen

20. COMPANY PROFILES: MOLECULAR DIAGNOSTICS SOLUTION PROVIDERS BASED IN ASIA

  • 20.1. Detailed Company Profiles
    • 20.1.1. Sysmex
      • 20.1.1.1. Company Overview
      • 20.1.1.2. Product Portfolio
      • 20.1.1.3. Financial Information
      • 20.1.1.4. Recent Developments and Future Outlook
  • 20.2. Brief Company Profiles
    • 20.2.1. BGI Genomics
      • 20.2.1.1. Company Overview
      • 20.2.1.2. Product Portfolio
    • 20.2.2. Sansure
    • 20.2.3. Seegene

21. PORTER'S FIVE FORCES ANALYSIS

  • 21.1. Methodology and Assumptions
  • 21.2. Key Parameters
    • 21.2.1. Threats of New Entrants
    • 21.2.2. Bargaining Power of Buyers
    • 21.2.3. Bargaining Power of Suppliers
    • 21.2.4. Threats of Substitute Products
    • 21.2.5. Rivalry among Existing Competitors
  • 21.3. Porter's Five Force Analysis: Harvey Ball Analysis
  • 21.4. Concluding Remarks

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

Show more
Product Code: RA100507

List of Tables

  • Table 16.1 Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters, Company Ownership, Type of Technology and Diagnostic Applications
  • Table 16.2 Other Leading Molecular Diagnostics Solution Providers: Information on Year of Establishment, Headquarters and Company Ownership
  • Table 18.1 Abbott: Company Overview
  • Table 18.2 Abbott: Product Portfolio
  • Table 18.3 Abbott: Recent Developments and Future Outlook
  • Table 18.4 Agilent Technologies: Company Overview
  • Table 18.5 Agilent Technologies: Product Portfolio
  • Table 18.6 Agilent Technologies: Recent Developments and Future Outlook
  • Table 18.7 BD: Company Overview
  • Table 18.8 BD: Product Portfolio
  • Table 18.9 BD: Recent Developments and Future Outlook
  • Table 18.10 Danaher: Company Overview
  • Table 18.11 Danaher: Product Portfolio
  • Table 18.12 Danaher: Recent Developments and Future Outlook
  • Table 18.13 Roche: Company Overview
  • Table 18.14 Roche: Product Portfolio
  • Table 18.15 Roche: Recent Developments and Future Outlook
  • Table 18.16 Thermo Fisher Scientific: Company Overview
  • Table 18.17 Thermo Fisher Scientific: Product Portfolio
  • Table 18.18 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 18.19 Bio-Rad: Company Overview
  • Table 18.20 Bio-Rad: Product Portfolio
  • Table 18.21 Illumina: Company Overview
  • Table 18.22 Illumina: Product Portfolio
  • Table 18.23 Hologic: Company Overview
  • Table 18.24 Hologic: Product Portfolio
  • Table 18.25 PerkinElmer: Company Overview
  • Table 18.26 PerkinElmer: Product Portfolio
  • Table 18.27 QuidelOrtho: Company Overview
  • Table 18.28 QuidelOrtho: Product Portfolio
  • Table 19.1 bioMerieux: Company Overview
  • Table 19.2 bioMerieux: Product Portfolio
  • Table 19.3 bioMerieux: Recent Developments and Future Outlook
  • Table 19.4 Grifols: Company Overview
  • Table 19.5 Grifols: Product Portfolio
  • Table 19.6 Grifols: Recent Developments and Future Outlook
  • Table 19.7 Siemens Healthineers: Company Overview
  • Table 19.8 Siemens Healthineers: Product Portfolio
  • Table 19.9 Siemens Healthineers: Recent Developments and Future Outlook
  • Table 19.10 DiaSorin: Company Overview
  • Table 19.11 DiaSorin: Product Portfolio
  • Table 19.12 Qiagen: Company Overview
  • Table 19.13 Qiagen: Product Portfolio
  • Table 20.1 Sysmex: Company Overview
  • Table 20.2 Sysmex: Product Portfolio
  • Table 20.3 Sysmex: Recent Developments and Future Outlook
  • Table 20.4 BGI Genomics: Company Overview
  • Table 20.5 BGI Genomics: Product Portfolio
  • Table 20.6 Sansure: Company Overview
  • Table 20.7 Sansure: Product Portfolio
  • Table 20.8 Seegene: Company Overview
  • Table 20.9 Seegene: Product Portfolio
  • Table 22.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)
  • Table 22.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)
  • Table 22.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)
  • Table 22.4 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035
  • Table 22.5 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)
  • Table 22.6 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)
  • Table 22.7 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035
  • Table 22.8 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)
  • Table 22.9 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)
  • Table 22.10 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)
  • Table 22.11 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)
  • Table 22.12 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)
  • Table 22.13 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035
  • Table 22.14 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)
  • Table 22.15 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)
  • Table 22.16 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)
  • Table 22.17 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035
  • Table 22.18 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)
  • Table 22.19 Molecular Diagnostics Market for In situ Hybridization, Till 2035 (USD Billion)
  • Table 22.20 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)
  • Table 22.21 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)
  • Table 22.22 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)
  • Table 22.23 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)
  • Table 22.24 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)
  • Table 22.25 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035
  • Table 22.26 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)
  • Table 22.27 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)
  • Table 22.28 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)
  • Table 22.29 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)
  • Table 22.30 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)
  • Table 22.31 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)
  • Table 22.32 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)
  • Table 22.33 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)
  • Table 22.34 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)
  • Table 22.35 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)
  • Table 22.36 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)
  • Table 22.37 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)
  • Table 22.38 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)
  • Table 22.39 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)
  • Table 22.40 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)
  • Table 22.41 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)
  • Table 22.42 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)
  • Table 22.43 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)
  • Table 22.44 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)
  • Table 22.45 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035
  • Table 22.46 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)
  • Table 22.47 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)
  • Table 22.48 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)
  • Table 22.49 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)
  • Table 22.50 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)
  • Table 22.51 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035
  • Table 22.52 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)
  • Table 22.53 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)
  • Table 22.54 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)
  • Table 22.55 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)
  • Table 22.56 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)
  • Table 22.57 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)
  • Table 22.58 Molecular Diagnostics Market in France, Till 2035 (USD Billion)
  • Table 22.59 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)
  • Table 22.60 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)
  • Table 22.61 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)
  • Table 22.62 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)
  • Table 22.63 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)
  • Table 22.64 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)
  • Table 22.65 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)
  • Table 22.66 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)
  • Table 22.67 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)
  • Table 22.68 Molecular Diagnostics Market in China, Till 2035 (USD Billion)
  • Table 22.69 Molecular Diagnostics Market in India, Till 2035 (USD Billion)
  • Table 22.70 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)
  • Table 22.71 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)
  • Table 22.72 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)
  • Table 22.73 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)
  • Table 22.74 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)
  • Table 22.75 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)
  • Table 22.76 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)
  • Table 22.77 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)
  • Table 22.78 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)
  • Table 22.79 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)
  • Table 22.80 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)
  • Table 22.81 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)
  • Table 22.82 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)
  • Table 22.83 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)
  • Table 22.84 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)
  • Table 22.85 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)
  • Table 22.86 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)
  • Table 22.87 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)
  • Table 22.88 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)
  • Table 22.89 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenues (FY23, USD Billion
  • Table 22.90 Molecular Diagnostic Solution: Distribution by Type of Technology
  • Table 22.91 Molecular Diagnostic Solution: Distribution by Diagnostic Applications
  • Table 22.92 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications
  • Table 22.93 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment
  • Table 22.94 Molecular Diagnostics Solution Providers: Distribution by Company Size
  • Table 22.95 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters
  • Table 22.96 Molecular Diagnostics Solution Providers: Distribution by Company Ownership
  • Table 22.97 Abbott: Financial Information (USD Billion)
  • Table 22.98 Agilent Technologies: Financial Information (USD Billion)
  • Table 22.99 BD: Financial Information (USD Billion)
  • Table 22.100 Danaher: Financial Information (USD Billion)
  • Table 22.101 Thermo Fisher Scientific: Financial Information (CHF Billion)
  • Table 22.102 bioMerieux: Financial Information (EUR Billion)
  • Table 22.103 Grifols: Financial Information (EUR Billion)
  • Table 22.104 Roche: Financial Information (CHF Billion)
  • Table 22.105 Siemens Healthineers: Financial Information (EUR Billion)
  • Table 22.106 Sysmex: Financial Information (JPY Billion)

List of Figures

  • Figure 2.1 Research Methodology: Research Assumptions
  • Figure 2.2 Research Methodology: Project Methodology
  • Figure 2.3 Research Methodology: Forecast Methodology
  • Figure 2.4 Research Methodology: Robust Quality Control
  • Figure 2.5 Research Methodology: Key Market Segmentations
  • Figure 5.1 Key Technologies Employed in Molecular Diagnostic Solution
  • Figure 5.2 Challenges in the Molecular Diagnostics Domain
  • Figure 6.1 Market Drivers
  • Figure 6.2 Market Restraints
  • Figure 6.3 Market Opportunities
  • Figure 6.4 Market Challenges
  • Figure 7.1 Global Molecular Diagnostics Market, Till 2035 (USD Billion)
  • Figure 7.2 Global Molecular Diagnostics Market, Conservative Scenario, till 2035 (USD Billion)
  • Figure 7.3 Global Molecular Diagnostics Market, Optimistic Scenario, till 2035 (USD Billion)
  • Figure 8.1 Molecular Diagnostics Market: Distribution by Test Type, Current Year and 2035
  • Figure 8.2 Molecular Diagnostics Market for Laboratory Testing, Till 2035 (USD Billion)
  • Figure 8.3 Molecular Diagnostics Market for Point-of-Care Testing, Till 2035 (USD Billion)
  • Figure 9.1 Molecular Diagnostics Market: Distribution by Type of Offering, Current Year and 2035
  • Figure 9.2 Molecular Diagnostics Market for Instruments, Till 2035 (USD Billion)
  • Figure 9.3 Molecular Diagnostics Market for In-house Instruments, Till 2035 (USD Billion)
  • Figure 9.4 Molecular Diagnostics Market for Outsourced Instruments, Till 2035 (USD Billion)
  • Figure 9.5 Molecular Diagnostics Market for Reagents, Till 2035 (USD Billion)
  • Figure 9.6 Molecular Diagnostics Market for Services, Till 2035 (USD Billion)
  • Figure 10.1 Molecular Diagnostics Market: Distribution by Sample Type, Current Year and 2035
  • Figure 10.2 Molecular Diagnostics Market for Blood, Serum and Plasma, Till 2035 (USD Billion)
  • Figure 10.3 Molecular Diagnostics Market for Urine, Till 2035 (USD Billion)
  • Figure 10.4 Molecular Diagnostics Market for Others, Till 2035 (USD Billion)
  • Figure 11.1 Molecular Diagnostics Market: Distribution by Type of Technology, Current Year and 2035
  • Figure 11.2 Molecular Diagnostics Market for PCR, Till 2035 (USD Billion)
  • Figure 11.3 Molecular Diagnostics Market for In Situ Hybridization, Till 2035 (USD Billion)
  • Figure 11.4 Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology, Till 2035 (USD Billion)
  • Figure 11.5 Molecular Diagnostics Market for Next Generation Sequencing, Till 2035 (USD Billion)
  • Figure 11.6 Molecular Diagnostics Market for Microarrays, Till 2035 (USD Billion)
  • Figure 11.7 Molecular Diagnostics Market for Mass Spectrometry, Till 2035 (USD Billion)
  • Figure 11.8 Molecular Diagnostics Market for Other Technologies, Till 2035 (USD Billion)
  • Figure 12.1 Molecular Diagnostics Market: Distribution by Therapeutic Area, Current Year and 2035
  • Figure 12.2 Molecular Diagnostics Market for Infectious Diseases, Till 2035 (USD Billion)
  • Figure 12.3 Molecular Diagnostics Market for COVID-19, Till 2035 (USD Billion)
  • Figure 12.4 Molecular Diagnostics Market for Respiratory Infections (Excluding COVID-19), Till 2035 (USD Billion)
  • Figure 12.5 Molecular Diagnostics Market for Healthcare-associated Infections, Till 2035 (USD Billion)
  • Figure 12.6 Molecular Diagnostics Market for Hepatitis, Till 2035 (USD Billion)
  • Figure 12.7 Molecular Diagnostics Market for HIV, Till 2035 (USD Billion)
  • Figure 12.8 Molecular Diagnostics Market for Sexually Transmitted Diseases, Till 2035 (USD Billion)
  • Figure 12.9 Molecular Diagnostics Market for Other Infectious Diseases, Till 2035 (USD Billion)
  • Figure 12.10 Molecular Diagnostics Market for Oncological Disorders, Till 2035 (USD Billion)
  • Figure 12.11 Molecular Diagnostics Market for Lung Cancer, Till 2035 (USD Billion)
  • Figure 12.12 Molecular Diagnostics Market for Breast Cancer, Till 2035 (USD Billion)
  • Figure 12.13 Molecular Diagnostics Market for Colorectal Cancer, Till 2035 (USD Billion)
  • Figure 12.14 Molecular Diagnostics Market for Prostate Cancer, Till 2035 (USD Billion)
  • Figure 12.15 Molecular Diagnostics Market for Gastric Cancer, Till 2035 (USD Billion)
  • Figure 12.16 Molecular Diagnostics Market for Other Oncological Disorders, Till 2035 (USD Billion)
  • Figure 12.17 Molecular Diagnostics Market for Cardiovascular Diseases, Till 2035 (USD Billion)
  • Figure 12.18 Molecular Diagnostics Market for Neurological Diseases, Till 2035 (USD Billion)
  • Figure 12.19 Molecular Diagnostics Market for Genetic Diseases, Till 2035 (USD Billion)
  • Figure 12.20 Molecular Diagnostics Market for Other Therapeutic Areas, Till 2035 (USD Billion)
  • Figure 13.1 Molecular Diagnostics Market: Distribution by End Users, Current Year and 2035
  • Figure 13.2 Molecular Diagnostics Market for Laboratories, Till 2035 (USD Billion)
  • Figure 13.3 Molecular Diagnostics Market for Large Laboratories, Till 2035 (USD Billion)
  • Figure 13.4 Molecular Diagnostics Market for Small and Medium-sized Laboratories, Till 2035 (USD Billion)
  • Figure 13.5 Molecular Diagnostics Market for Hospitals, Till 2035 (USD Billion)
  • Figure 13.6 Molecular Diagnostics Market for Other End Users, Till 2035 (USD Billion)
  • Figure 14.1 Molecular Diagnostics Market: Distribution by Geographical Regions, Current Year and 2035
  • Figure 14.2 Molecular Diagnostics Market in North America, Till 2035 (USD Billion)
  • Figure 14.3 Molecular Diagnostics Market in the US, Till 2035 (USD Billion)
  • Figure 14.4 Molecular Diagnostics Market in Canada, Till 2035 (USD Billion)
  • Figure 14.5 Molecular Diagnostics Market in Europe, Till 2035 (USD Billion)
  • Figure 14.6 Molecular Diagnostics Market in Austria, Till 2035 (USD Billion)
  • Figure 14.7 Molecular Diagnostics Market in Belgium, Till 2035 (USD Billion)
  • Figure 14.8 Molecular Diagnostics Market in France, Till 2035 (USD Billion)
  • Figure 14.9 Molecular Diagnostics Market in Germany, Till 2035 (USD Billion)
  • Figure 14.10 Molecular Diagnostics Market in Italy, Till 2035 (USD Billion)
  • Figure 14.11 Molecular Diagnostics Market in the Netherlands, Till 2035 (USD Billion)
  • Figure 14.12 Molecular Diagnostics Market in Poland, Till 2035 (USD Billion)
  • Figure 14.13 Molecular Diagnostics Market in Spain, Till 2035 (USD Billion)
  • Figure 14.14 Molecular Diagnostics Market in Switzerland, Till 2035 (USD Billion)
  • Figure 14.15 Molecular Diagnostics Market in the UK, Till 2035 (USD Billion)
  • Figure 14.16 Molecular Diagnostics Market in Rest of the Europe, Till 2035 (USD Billion)
  • Figure 14.17 Molecular Diagnostics Market in Asia, Till 2035 (USD Billion)
  • Figure 14.18 Molecular Diagnostics Market in China, Till 2035 (USD Billion)
  • Figure 14.19 Molecular Diagnostics Market in India, Till 2035 (USD Billion)
  • Figure 14.20 Molecular Diagnostics Market in Indonesia, Till 2035 (USD Billion)
  • Figure 14.21 Molecular Diagnostics Market in Japan, Till 2035 (USD Billion)
  • Figure 14.22 Molecular Diagnostics Market in Singapore, Till 2035 (USD Billion)
  • Figure 14.23 Molecular Diagnostics Market in South Korea, Till 2035 (USD Billion)
  • Figure 14.24 Molecular Diagnostics Market in Thailand, Till 2035 (USD Billion)
  • Figure 14.25 Molecular Diagnostics Market in Rest of the Asia, Till 2035 (USD Billion)
  • Figure 14.26 Molecular Diagnostics Market in Latin America, Till 2035 (USD Billion)
  • Figure 14.27 Molecular Diagnostics Market in Brazil, Till 2035 (USD Billion)
  • Figure 14.28 Molecular Diagnostics Market in Argentina, Till 2035 (USD Billion)
  • Figure 14.29 Molecular Diagnostics Market in Mexico, Till 2035 (USD Billion)
  • Figure 14.30 Molecular Diagnostics Market in Rest of Latin America, Till 2035 (USD Billion)
  • Figure 14.31 Molecular Diagnostics Market in Middle East and North Africa, Till 2035 (USD Billion)
  • Figure 14.32 Molecular Diagnostics Market in Egypt, Till 2035 (USD Billion)
  • Figure 14.33 Molecular Diagnostics Market in Israel, Till 2035 (USD Billion)
  • Figure 14.34 Molecular Diagnostics Market in Saudi Arabia, Till 2035 (USD Billion)
  • Figure 14.35 Molecular Diagnostics Market in Rest of Middle East and North Africa, Till 2035 (USD Billion)
  • Figure 14.36 Molecular Diagnostics Market in Rest of the World, Till 2035 (USD Billion)
  • Figure 14.37 Molecular Diagnostics Market in Australia, Till 2035 (USD Billion)
  • Figure 14.38 Molecular Diagnostics Market in New Zealand, Till 2035 (USD Billion)
  • Figure 15.1 Molecular Diagnostics Market: Distribution of Leading Players by Annual Revenue (FY23, USD Billion)
  • Figure 16.1 Molecular Diagnostic Solution: Distribution by Type of Technology
  • Figure 16.2 Molecular Diagnostic Solution: Distribution by Diagnostic Applications
  • Figure 16.3 Molecular Diagnostic Solution: Distribution by Type of Technology and Diagnostic Applications
  • Figure 16.4 Molecular Diagnostics Solution Providers: Distribution by Year of Establishment
  • Figure 16.5 Molecular Diagnostics Solution Providers: Distribution by Company Size
  • Figure 16.6 Molecular Diagnostics Solution Providers: Distribution by Location of Headquarters
  • Figure 16.7 Molecular Diagnostics Solution Providers: Distribution by Company Ownership
  • Figure 17.1 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Very Large Players
  • Figure 17.2 Molecular Diagnostic Solution Providers: Competitiveness Analysis of Large Players
  • Figure 17.3 Roche: Benchmarking Analysis
  • Figure 17.4 Abbott: Benchmarking Analysis
  • Figure 17.5 Thermo Fisher Scientific: Benchmarking Analysis
  • Figure 17.6 Qiagen: Benchmarking Analysis
  • Figure 17.7 bioMerieux: Benchmarking Analysis
  • Figure 17.8 DiaSorin: Benchmarking Analysis
  • Figure 17.9 Illumina: Benchmarking Analysis
  • Figure 17.10 Sysmex: Benchmarking Analysis
  • Figure 17.11 Perkin Elmer: Benchmarking Analysis
  • Figure 17.12 Bio-Rad: Benchmarking Analysis
  • Figure 17.13 Leading Molecular Diagnostic Solution Providers: Benchmarking by Competitiveness
  • Figure 17.14 Leading Molecular Diagnostic Solution Providers: Benchmarking by Type of Technology Score
  • Figure 17.15 Leading Molecular Diagnostic Solution Providers: Benchmarking by Diagnostic Applications Score
  • Figure 18.1 Abbott: Financial Information (USD Billion)
  • Figure 18.2 Agilent Technologies: Financial Information (USD Billion)
  • Figure 18.3 BD: Financial Information (USD Billion)
  • Figure 18.4 Danaher: Financial Information (USD Billion)
  • Figure 18.5 Thermo Fisher Scientific: Financial Information (CHF Billion)
  • Figure 19.1 bioMerieux: Financial Information (EUR Billion)
  • Figure 19.2 Grifols: Financial Information (EUR Billion)
  • Figure 19.3 Roche: Financial Information (CHF Billion)
  • Figure 19.4 Siemens Healthineers: Financial Information (EUR Billion)
  • Figure 20.1 Sysmex: Financial Information (JPY Billion)
  • Figure 21.1 Threats of New Entrants
  • Figure 21.2 Bargaining Power of Buyers
  • Figure 21.3 Bargaining Power of Suppliers
  • Figure 21.4 Threats of Substitute Products
  • Figure 21.5 Rivalry among Existing Competitors
  • Figure 21.6 Porter's Five Force Analysis: Harvey Ball Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!